Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1995-2-9
|
pubmed:abstractText |
Immunosuppressive drugs currently available for the treatment of autoimmune diseases display a narrow therapeutic window between efficacy and toxic side effects. The use of combinations of drugs that have a synergistic effect may expand this window and reduce the risk of toxicity. We evaluated the combination effect of rapamycin (Rapa) and cyclosporin A (CsA) in an autoimmune disease model of the eye. The dose-effect relationship of Rapa with CsA was measured in vitro on the inhibition of proliferation of retinal S-Ag-primed lymphocytes. A median effect analysis was performed and a combination index (CI) calculated for 50% inhibition of proliferation. Rapa and CsA were markedly synergistic over a wide dose range (lowest CI = 0.31). Calculated dose reduction factors indicated that Rapa could be reduced nine-fold and CsA reduced five-fold when these drugs were used in combination. These reduced doses were tested in vivo for the treatment of experimental autoimmune uveoretinitis (EAU). Twelve of 15 rats treated with CsA, 2 mg/kg/day, developed EAU with a median severity of 2.5. Fourteen of 15 rats treated with Rapa, 0.01 mg/kg/day, developed EAU with a median severity of 3.25. Complete inhibition of EAU was achieved in all 15 animals treated with the combination of Rapa and CsA (combined vs CsA alone, p < 0.0002; combined vs Rapa alone, p < 0.00001). The demonstrated synergistic relationship between Rapa and CsA will allow the use of reduced doses of each drug to achieve a therapeutic effect. The use of lower doses may reduce the toxicity of these drugs for the treatment of autoimmune uveitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Arrestin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Eye Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Polyenes,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
154
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
922-7
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7814893-Animals,
pubmed-meshheading:7814893-Antigens,
pubmed-meshheading:7814893-Arrestin,
pubmed-meshheading:7814893-Autoimmune Diseases,
pubmed-meshheading:7814893-Cyclosporine,
pubmed-meshheading:7814893-Drug Synergism,
pubmed-meshheading:7814893-Eye Proteins,
pubmed-meshheading:7814893-Immunosuppressive Agents,
pubmed-meshheading:7814893-Lymph Nodes,
pubmed-meshheading:7814893-Lymphocyte Activation,
pubmed-meshheading:7814893-Male,
pubmed-meshheading:7814893-Polyenes,
pubmed-meshheading:7814893-Rats,
pubmed-meshheading:7814893-Rats, Inbred Lew,
pubmed-meshheading:7814893-Retinitis,
pubmed-meshheading:7814893-Sirolimus,
pubmed-meshheading:7814893-Uveitis
|
pubmed:year |
1995
|
pubmed:articleTitle |
Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis.
|
pubmed:affiliation |
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892.
|
pubmed:publicationType |
Journal Article
|